+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Rare ovarian cancers (ROC) in France: Analysis of the first 100 patients (pts) prospectively included through an on-line observatory



Rare ovarian cancers (ROC) in France: Analysis of the first 100 patients (pts) prospectively included through an on-line observatory



Journal of Clinical Oncology 26(15_Suppl): 16506-16506



NlmCategory="UNASSIGNED">16506 Background: A website ( www.ovaire-rare.org ) dedicated to germ cell and sex cord-stromal malignant tumors was developed in France to collect clinical cases and tumor samples of these uncommon ovarian cancers. The ultimate goal of this website is to better assess clinical and biological prognosis factors of ROC and to evaluate medical practice in the country. Adult pts with histological diagnosis of ROC in first-line or in first relapse were eligible. From 03/2002 to 12/2007, 157 pts have been included and the first 100 were evaluated. Pts characteristics were: inclusion at diagnosis (78 pts) or in first relapse (22), histology: sex cord-stromal (61%), germ cell (30%), others (5%), median age 44 y. (range 18-79), median tumor size 12 cm (range 1-30), FIGO stage I 73%, II 10%, III 14%, IV 3%, ECOG PS 0 (88%). Review of histology by a panel was performed for 66 pts with discrepancy from initial diagnosis in 36%. Pts had initial conservative surgery in 56% and only 10% had lymph node dissection. 56 pts received BEP regimen (35 in first line, 13 in relapse). Grade 3-4 toxicity was observed in 26% of pts with 1 toxic death. Relapse occurred in 11/78 pts in first line and 5 died. OS at 5y was 94% and median PFS were 64 months (0-332). Independent prognostic factors for PFS were histology (other vs. germ cell or stromal; p=0.04), age (<60y vs. ≥60, p=0.03), stage (I/II vs. III/IV, p0.008), previous pregnancy (yes vs. no, p=0.04) and tumor size (<10 or >10cm, p=0.04). No patient in first line relapsed in optimal surgery subgroup compared to 16% for "other" surgery, p=NS. This on-line observatory on ROC offers an unique opportunity to better assess medical practice for these tumors in France. The histological discrepancies between initial diagnosis and second opinion confirm the importance to add a systematic slide review before treating ROC. The place of node dissection in these tumors with mostly a localized stage has to be better defined. Extension of the observatory to other rare gynecologic malignant tumor is planned. No significant financial relationships to disclose.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 058694154

Download citation: RISBibTeXText

PMID: 27948761


Related references

Rare ovarian tumours: therapeutic strategies in 2010, national website observatory for rare ovarian cancers and delineation of referent centers in France. Bulletin du Cancer 97(1): 123-135, 2010

Management of rare ovarian cancers: the experience of the French website "Observatory for rare malignant tumours of the ovaries" by the GINECO group: interim analysis of the first 100 patients. Gynecologic Oncology 119(1): 53-59, 2010

Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. Journal of Clinical Oncology 24(7): 1127-1135, 2006

Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecologic Oncology 114(2): 199-205, 2009

Germline BRCA1 mutations in patients from 84 families with breast and/or ovarian cancers in northern France. European Journal of Cancer Prevention 7(Suppl. 1): S7, 1998

Germline BRCA1 mutations in patients from 36 families with breast and/or ovarian cancers in Northern France. Bulletin du Cancer 84(1): 41-46, 1997

Germline BRCA1 mutations in patients from 36 families with breast and ovarian cancers in Northern France. Proceedings of the American Association for Cancer Research Annual Meeting 37: 264, 1996

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 115(6): 1234-1244, 2009

Observatory of management of GERD in France by gastroenterologists Endoscopic base-line data. Gastroenterology 122(4 Suppl 1): A 584, 2002

Mutational analysis of MLHI and MSH2 in 25 prospectively-acquired RER+ endometrial cancers. Genes Chromosomes & Cancer 18(3): 219-227, 1997

Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecologic Oncology 109(2): 174-181, 2008

Germ-line mutation of BRCA1 in patients with breast and/or ovarian cancer in high risk families in Northern France. Bulletin du Cancer 84(1): 41-46, 1997

Hemostatic and fibrinolytic status in patients with ovarian cancer and benign ovarian cysts: could D-dimer and antithrombin III levels be included as prognostic markers for survival outcome?. Clinical and Applied Thrombosis/Hemostasis 7(2): 141-148, 2001

The dilemma of rare species in bioassessment To be included or not to be included, that is the question. IAGLR Conference Program & Abstracts 44: 111, 2001